Funding for this research was provided by:
Ontario Institute for Cancer Research (IA-016)
Princess Margaret Cancer Foundation
Received: 14 November 2019
Accepted: 10 March 2020
First Online: 3 April 2020
Ethics approval and consent to participate
: The research was performed in accordance with the policies of the University Health Network (UHN) Research Ethics Board (Toronto, Ontario, Canada, REB ID# 09–0828).The primary patient specimens were collected as part of the UHN Program in Biospecimen Sciences from consenting patients. These biobanked specimens were obtained with broad consent and utilized in accordance with the banking consent.The TMA used was a commercially available set of tumours (BioMax).
: Not applicable.
: The authors declare that they have no competing interests.